SEC Form F-10POS filed by Oncolytics Biotech Inc.
As filed with the U.S. Securities and Exchange Commission on March 31, 2026.
Registration Statement No. 333-140460
Registration Statement No. 333-140529
Registration Statement No. 333-151513
Registration Statement No. 333-167250
Registration Statement No. 333-182260
Registration Statement No. 333-197633
Registration Statement No. 333-224432
Registration Statement No. 333-239025
Registration Statement No. 333-265510
Registration Statement No. 333-281009
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT NO. 333-140460 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT NO. 333-140529 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT NO. 333-151513 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT NO. 333-167250 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT NO. 333-182260 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT NO. 333-197633 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT NO. 333-224432 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT NO. 333-239025 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT NO. 333-265510 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-10 REGISTRATION STATEMENT NO. 333-281009
UNDER THE SECURITIES ACT OF 1933 |
ONCOLYTICS BIOTECH INC.
(Exact name of Registrant as specified in its charter)
| Nevada | 98-0541667 | |
| (State or other jurisdiction of incorporation or organization ) |
(I.R.S. Employer Identification No.) |
4350 Executive
Drive, Suite 325
San Diego, California, 92121
(403) 670-7377
(Address and Telephone number of Registrant’s Principal Executive Offices)
Jared Kelly
Chief Executive Officer
4350 Executive Drive, Suite 325
San Diego, California 92121
(403) 670-7377
(Name, Address (including zip code) and Telephone Number (including Area Code) of Agent for Service in the United States)
Copies to:
|
Christopher J. Clark, Esq. 555 Eleventh Street N.W., Suite 1000 Washington, D.C. 20004 (202) 637-2200 |
Approximate date of proposed sale to the public:
Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statements..
Province of Alberta, Canada
(Principal jurisdiction regulating this offering)
It is proposed that this filing shall become effective (check appropriate box):
| A. | ¨ Upon filing with the Commission, pursuant to Rule 467(a) (if in connection with an offering being made contemporaneously in the United States and Canada). |
| B. | ¨ At some future date (check the appropriate box below): |
| 1. | x pursuant to Rule 467(b) on April 7, 2026 (date) at 10:00 p.m. Eastern time (time) (designate a time not sooner than 7 calendar days after filing). |
| 2. | ¨ pursuant to Rule 467(b) on __(date) at ___(time) (designate a time 7 calendar days or sooner after filing) because the securities regulatory authority in the review jurisdiction has issued a receipt or notification of clearance on ___(date). |
| 3. | ¨ pursuant to Rule 467(b) as soon as practicable after notification of the Commission by the Registrant or the Canadian securities regulatory authority of the review jurisdiction that a receipt or notification of clearance has been issued with respect hereto. |
| 4. | ¨ after the filing of the next amendment to this Form (if preliminary material is being filed). |
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to the home jurisdiction’s shelf prospectus offering procedures, check the following box. ¨
DEREGISTRATION OF SECURITIES
These post-effective amendments relate to the following Registration Statements on Form F-10 (collectively, the “Registration Statements”):
| · | Registration Statement on Form F-10 (File No. 333-140460) initially filed with the U.S. Securities and Exchange Commission (the “SEC”) by Oncolytics Biotech Inc. (the “Company”) on February 2, 2007 and as amended, pertaining to the registration of offers and sales by the Company of units (“Units”); |
| · | Registration Statement on Form F-10 (File No. 333-140529) initially filed with the SEC by the Company on February 8, 2007 and as amended, pertaining to the registration of offers and sales by the Company of common shares (“Common Shares”); |
| · | Registration Statement on Form F-10 (File No. 333-151513) initially filed with the SEC by the Company on June 6, 2008 and as amended, pertaining to the registration of offers and sales by the Company of Common Shares, subscription receipts, warrants, Units (collectively “Securities”) and debt securities; |
| · | Registration Statement on Form F-10 (File No. 333-167250) initially filed with the SEC by the Company on June 2, 2010 and as amended, pertaining to the registration of offers and sales by the Company of Securities; |
| · | Registration Statement on Form F-10 (File No. 333-182260) initially filed with the SEC by the Company on June 21, 2012 and as amended, pertaining to the registration of offers and sales by the Company of Securities; |
| · | Registration Statement on Form F-10 (File No. 333-197633) initially filed with the SEC by the Company on July 25, 2014 and as amended, pertaining to the registration of offers and sales by the Company of Securities; |
| · | Registration Statement on Form F-10 (File No. 333-224432) initially filed with the SEC by the Company on April 25, 2018 and as amended, pertaining to the registration of offers and sales by the Company of Securities; |
| · | Registration Statement on Form F-10 (File No. 333-239025) initially filed with the SEC by the Company on June 8, 2020 and as amended, pertaining to the registration of offers and sales by the Company of Securities; |
| · | Registration Statement on Form F-10 (File No. 333-265510) initially filed with the SEC by the Company on June 10, 2022 and as amended, pertaining to the registration of offers and sales by the Company of Securities; and |
| · | Registration Statement on Form F-10 (File No. 333-281009) initially filed with the SEC by the Company on July 25, 2024 and as amended, pertaining to the registration of offers and sales by the Company of Securities. |
The Company hereby withdraws the Registration Statements, including all amendments and exhibits thereto, with respect to the unsold portion of securities registered thereon.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-10 and has duly caused these post-effective amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on the 31st day of March, 2026.
| ONCOLYTICS BIOTECH INC. | ||
| By: | /s/ Jared Kelly | |
| Jared Kelly | ||
| Chief Executive Officer | ||
No other person is required to sign these post-effective amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.